

Finance Diversification Strategies for Health Systems to Consider

Health Finance & Management Michigan Chapter September May 2025

Authored by: Michael Haas



RSM Introductions



Michael Haas

Director and Health Care Senior Analyst

Michael has over 15 years of health care revenue cycle experience and system implementations. He has lead process improvement engagements in revenue cycle successfully growing the bottom line and has built educational materials used to train coders and physicians on compliant billing coding practices.

As one of RSM's health care analysts, Michael contributes thought leadership articles and content on industry trends affecting middle market businesses

Michael.Haas@rsmus.com

Topics To Cover

- *Trends Shaping the Need to Consider A Revenue Diversification Strategy*
- *Regulatory issues for health care organizations to consider*
- *Revenue Diversification Strategies from Joint Ventures to Alternative Investments*

Course Objectives


By the end of this course, you will be able to:

- *Identify the economic and industry pressures driving health systems to diversify their revenue streams, such as declining operating margins, rising costs, and increased competition from non-traditional health care players.*
 - *Understand the key C-suite considerations and steps to identify financial diversification strategies*
 - *Identify the organizational capabilities, planning approaches, and risk management practices necessary for effective diversification.*
- 


Economic outlook



Negative risks to the outlook



Positive risks to the outlook



Current challenges: tariffs

While the Trump administration has waived on its implementation of some tariffs on imported goods, American Hospital Association (AHA) President and CEO, Rick Pollack, has called for exceptions for medical devices and drugs that are essential to “safe, effective care”.

75%

Of available U.S.- marketed medical devices are manufactured out of the country*

69%

Of available U.S.- marketed medical devices are manufactured **solely** out of the country*

14%


Of total U.S.- marketed medical devices are manufactured in China*

How are healthcare organizations responding?

- ✓ Monitor the political climate and changing policies
- ✓ Identify items that are at risk and work with manufacturers, where required
- ✓ Review contracts to identify products that are not price protected
- ✓ Quantify current and future financial impact of the tariffs
- ✓ Leverage Group Purchasing Organization (GPOs) and distributor reports to receive information on tariff impacts
- ✓ Determine if there are alternative products that can be sourced from countries not impacted by tariffs
- ✓ Renegotiate contracts to include price protection language

*According to Medical Economics, Article “If tariffs go through, the cost of medical devices will go up”, November 11, 2024

Current challenges: inflation




What are healthcare organizations doing about it?

- Review accounts payable and purchase order data
- Benchmark supply and purchased services spend
- Review the vendor agreement to validate increase or confirm price protection
- Review alternative products/vendors
- Renegotiate contract with lower pricing
- Consider going to RFP

*According to a February 2025 article published by Becker's Hospital CFO Report


Tight labor market – plenty of jobs to choose from



Source: BLS, RSM US LLP

Source: Bloomberg, RSM

Age demographic shifts - shifting how care is delivered




Source: Bloomberg, RSM

Labor supply has not fully recovered from COVID


Post-pandemic change in [US health expenditure dollars](#) vs. employment headcount by sector

Post-Pandemic Change in Expenditures vs Employment




Source: AACM, BLS, RSM

Reimbursement lags wage increases




2015 = 100
Source: BLS, CMS, RSM

The cost of capital will remain elevated




Source: Bloomberg, RSM

Long term municipal health care financing remains elevated



Source: Bloomberg

Expect future financing to increase with the looming debt maturity wall



Source: Bloomberg

Regulatory issues for health care organizations to consider

One Big Beautiful Bill Act

\$988 billion Medicaid cuts

Medicaid Expansion

- Affordable Care Act
- Undocumented immigrants
- Mandatory Cost Sharing

Eligibility Policies

- Work Requirements
- Eligibility Determinations
- Verification
- Coverage

Financing

- Provider taxes
- DSH payments
- State directed payments
- Waivers

Long Term Care

Nursing home staffing
Home equity limits

Access

- Provider choice and type of care
- Out-of-state enrollment
- Screening requirements


Prescription Drugs

- Pricing and rules for Pharmacy benefit managers


[CBO Estimates](#)

OBBBA Timeline


Health policy



Top 5 Medicaid funding cuts - \$851B




16.5 million uninsured



\$50B Rural Health Transformation Fund

Medicaid Cuts vs. Relief Fund



Rural Health Transformation Fund priorities

Improve Access and health care outcomes

Data and technology solutions

Strategic
partnerships

Economic
opportunity

Financial
solvency

Risk
management

Long term strategic planning

Infrastructure

Technology

Margin
improvement

Community
outreach and
education

Joint
ventures

Community
benefit

On the horizon



MEDICARE
ADVANTAGE



340B DRUG PRICING



SITE NEUTRAL



If there isn't enough labor to keep up with demand, then what are we going to do?!



2025 reimbursement update

- **Medicare conversion factor decreased 2.83% to \$32.35 in 2025**

- Directly affects services billed under Medicare Physician Fee Schedule
- Indirectly affects direction of reimbursement for other services
- Trump Admin expected to mitigate reductions for 2026
- Medicare Advantage growth has slowed, and Congress is concerned with cost. Still, the program remains popular and there is talk of making MA the default option for retired seniors.
- AMA released [new telemedicine codes](#) for synchronous audio/video meetings and synchronous audio-only meetings
 - Affect on reimbursement will vary by provider. Some providers will see a boost because it expands patient base, others may see reduction if patients opt for telehealth compared to in-person
 - Will vary by specialty and geography

Selected specialty-specific changes

- **Dermatology:** 88305 (Surgical pathology codes) 2% global decrease and 1% and 3% for tech/prof components. High volume code for most practices.
- **Substance abuse:** expansion of audio-only telehealth visits for opioid treatment programs, including initiating methadone treatment. CMS expects to extend coverage to new FDA-approved opioid treatment medication Opvee and Brixadi
 - Providers limited to diagnosing and treating mental illness will be able to bill for interprofessional consultations, which may open new revenue streams for some clients
- **Fertility:** Significant expansion of IVF coverage, including to Federal government employees and retirees. Private plans continue to expand coverage.
- **Dental:** some Medicare Advantage plans are reducing dental benefits to offset rising costs in other areas of care
- **Home care:** Net increase of 0.5% Medicare reimbursement increase in 2025. Expansion of home health value-based care purchasing models will likely benefit most providers.


Health care funding may be cut to pay for tax extensions

Policy area*	Estimated 10-year budget savings (\$ billions)
Hospital site-neutral payment	\$156
Medicaid Work Requirements	\$135
Reduce Medicaid Expansion Rate	\$596
Caps on Federal Medicaid Spending	\$907

Policy areas are sorted by most to least likely affected, according to Bloomberg Intelligence

Source: Bloomberg Intelligence, Congressional Budget Office


Marketplace subsidies likely to expire in 2026



- 2.2 million people expected to lose coverage in '26
- 3.7 million in '27
- GOP particularly critical of subsidies to individuals making over \$60k
- Potential \$15b hit to insurers
- ACA in general is expected to remain unchanged

Regulatory scrutiny heats up for private equity health care transactions

Requirements in Effect: ■ Yes ■ Yes + Pending Legislation ■ Pending Legislation ■ No



Source: McDermott Will & Emery

What are these Regulatory Issues?

Regulator issues continue to take shape and change the way private equity groups strategically position themselves in the marketplace.

Increased Federal Scrutiny

The FTC, DOJ, and HHS have launched a cross-government inquiry into private equity's influence on health care.

Antitrust Concerns

There is heightened attention on potential anticompetitive practices, particularly in emergency rooms, where private equity firms oversee a significant portion.

Debt and Financial Stability

Private equity firms often use significant amounts of debt to finance acquisitions. This can lead to financial instability for the acquired health care providers, potentially affecting their ability to operate effectively

Billing Practices

Private equity-owned health care providers have been scrutinized for aggressive billing practices. This includes surprise billing, where patients receive unexpected charges for out-of-network services. .

Margin Pressures

Ethical & Clinical Implications

The ethical and clinical impacts of private equity in health care are under scrutiny, with concerns about how profit motives might influence medical decisions.

State Level Regulations


Various states are implementing new laws requiring regulatory approval for health care transactions involving private equity, aiming to ensure transparency and protect patient interests.



Revenue Diversification Strategies from Joint Ventures to Alternative Investments

Joint venture focus areas for health systems


Respondents indicated they would consider a joint venture partnership in the following service line areas:



Source: VMG Health

Investment in technology will increase

Health care technology VC investment from strategic investors



Source: Pitchbook, RSM

IDC expects health care technology spend in 2025 to increase 8% to \$231.2 billion

IDC further predicts that 10% of clinical time will be freed up by generative AI in 2025

The global artificial intelligence in health care market is expected to grow 40% per year through 2029 to \$174 billion


McKinsey estimates broad adoption of AI in the US health care system could save \$360 billion

Surveys show executive are using technology to diversify revenue streams

Exhibit 1: CEOs identify their AI investment priorities

Percentage share of respondents

Healthcare and Life Sciences



■ Invest heavily to be a market leader
 ■ Invest incrementally to build capabilities
 ■ Not investing in this area yet

Source: Oliver Wyman

Health care automation investments




- Bridge gap of labor needs
- Support margin improvement
- Align people, processes, **and technology**

Artificial Intelligence



Let's address the elephant in the room first....



“



78% of middle market companies-which includes health care organizations-indicating they are using AI

Nine out of 10 respondents indicated they expect to increase their generative AI budget next year

RSM Middle market AI survey 2024: US and Canada

”


Labor and AI discussion trend, one is unlike the other



Worldwide AI Opportunity – Most profound change in % impact of GDP



Generative AI market outlook - \$ Trillion



Examples of leveraging technology

RSM partners with EQUIFAX to utilize their proprietary tool **Supplier Risk Solution™** and provide clients visibility into their supply chain and the risk profile of their suppliers.

Equifax leverages its extensive databases to deliver real-time updates on global events, helping you assess potential disruptions to your operations and overall supplier risk.

Supplier risk ratings are aggregated based on six risk factors:

- Financial
- Environmental, social, and governance (ESG)
- Cyber
- Restrictions
- Geopolitical
- Catastrophic



Pyramid of Data and AI

Considerations:

- What needs to be measured and improved?
- What data do you need to evaluate the problem?
- What data do you have access to?

Artificial Intelligence

Automation, Machine Learning, quick time to value

Move, Transform, Store, Visualize

Data foundation designed to scale and facilitate data storage, transformation, and governance

Collect Data


Standardize data intake processes

AI Education, Strategy, Use Cases


Defined strategy, use cases, stakeholder buy-in, technology, and data

When done right, improved patient outcomes guided by data insights can occur!

Congenital Heart Defects (CHD) case study



Responsible AI Governance Framework



Generative AI Use Cases (Hospitals & Physician Groups)



To Recap

- *Diversification enables health systems to strengthen financial resilience by generating new revenue streams, reducing reliance on traditional hospital operations, and better positioning themselves against industry disruptions and shifting patient preferences.*
 - *Leading strategies include monetizing existing capabilities (such as transforming internal services into profit centers), expanding into ambulatory and outpatient care, and investing in innovation through partnerships, acquisitions, or direct investment in health care startups.*
 - *Successful diversification requires aligning new ventures with organizational goals, ensuring operational readiness, and building capabilities that support both short-term cash flow and long-term value for core hospital operations.*
- 

Q&A



Thank you!



THE POWER OF BEING UNDERSTOOD
ASSURANCE | TAX | CONSULTING



RSM US LLP

30 South Wacker Dr
STE 3300
Chicago, IL 60606

T 312.634.3400
rsmus.com

This document contains general information, may be based on authorities that are subject to change, and is not a substitute for professional advice or services. This document does not constitute audit, tax, consulting, business, financial, investment, legal or other professional advice, and you should consult a qualified professional advisor before taking any action based on the information herein. RSM US LLP, its affiliates and related entities are not responsible for any loss resulting from or relating to reliance on this document by any person. Internal Revenue Service rules require us to inform you that this communication may be deemed a solicitation to provide tax services. This communication is being sent to individuals who have subscribed to receive it or who we believe would have an interest in the topics discussed.

RSM US LLP is a limited liability partnership and the U.S. member firm of RSM International, a global network of independent audit, tax and consulting firms. The member firms of RSM International collaborate to provide services to global clients, but are separate and distinct legal entities that cannot obligate each other. Each member firm is responsible only for its own acts and omissions, and not those of any other party. Visit rsmus.com/aboutus for more information regarding RSM US LLP and RSM International.

RSM, the RSM logo and The power of being understood are registered trademarks of RSM International Association, used under license.

© 2024 RSM US LLP. All Rights Reserved.